Cord Blood Registry Files Opposition To Americord's CordAdvantage Mark

NEW YORK, Sept. 23, 2013 /PRNewswire/ -- Discovery is set to begin on September 25^th in a trademark opposition case brought by Cord Blood Registry against rival private cord blood bank Americord. Americord has enjoyed a considerable jump in cord blood sales and market share during 2012, boasting year-over-year revenue growth of over 1,200%. In the case, which was brought before the Trademark Trial And Appeal Board of the United States Patent and Trademark Office, Cord Blood Registry filed a claim opposing Americord's use of the trademark application for CordAdvantage, alleging that it infringes upon Cord Blood Registry's trademark CellAdvantage. Americord is disputing the trademark opposition.

Americord's CordAdvantage product is currently in the late stages of development under the direction of the company's Executive Medical Director Dr. Robert Dracker. CordAdvantage will utilize a proprietary process to maximize the volume of stem cells that can be harvested from cord blood found in the placenta immediately following the birth of a baby. Cord blood stem cells, which are currently being used to treat more than 80 diseases and conditions, can only be collected and preserved immediately following the birth of a baby. Increasing the volume of stem cells that can be collected has been the focus of significant efforts in the scientific community.

Cord Blood Registry's CellAdvantage system refers to a variety of processes, protocols, and equipment the company uses to optimize the amount and quality of stem cells harvested from cord blood.

Since its founding in 2008, Americord has been committed to bringing cutting-edge scientific advances and the highest quality cord blood banking services to expecting parents at dramatically lower cost than other leading cord blood banks. "We expect CordAdvantage to be a game-changer in the industry because of the value it will offer to parents seeking to give their children access to the most advanced medical treatments today and in the future," said Martin Smithmyer, President and CEO of Americord. "We will not let the case brought by Cord Blood Registry get in the way of bringing CordAdvantage to market where it can help expecting parents and their children."

Americord is the fastest growing cord blood bank in the United States with year-over-year growth of over 1,200% in its most recent fiscal year. The company attributes its exceptional growth to its ability to offer equal or better quality of products and services at approximately 50% lower cost than other leading cord blood banks. Americord has achieved this cost differential in large part through minimizing its marketing expenses and passing the savings through to customers.

About Americord

Americord is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's website at cordadvantage.com for more information. You may also find Americord on Facebook and follow the company on Twitter.

SOURCE Americord Registry